EZH2 has been shown to inhibit lung cancer cell proliferation by silencing NFE2L2 expression, which led to an increased trimethylation of histone H3 lysine 27 (H3K27me3) marks at its promoter [92]. Here, NFE2L2 is linked to lung cancer.